Q&A with Tony MacDonald, Spectrum - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Tony MacDonald, Spectrum
A Q&A with Spectrum Laboratories President Tony MacDonald.

Pharmaceutical Technology
Volume 35, Issue 1, pp. 89



Q&A with
Tony MacDonald, president of Spectrum Laboratories

PharmTech:
What is the biggest industry challenge you're now facing?

MacDonald:
The biggest industry challenge that we see is reducing the cost of single-use technology. Making the technology more affordable would broaden accessibility to the rapid scale-up of vaccine production and help avoid batch-to-batch contamination.

PharmTech:

How do you stay abreast of new developments in the industry?

MacDonald:
Spectrum Laboratories stays abreast of new developments in the pharmaceutical, biopharmaceutical, and biotech markets by maintaining direct contact with end users through our direct sales and marketing team and our distribution partners across the globe. We also attend industry conferences and seminars frequently.

PharmTech:
Do you see a new industry trend emerging?

MacDonald:
The industry trend that is emerging is the replacement of processing equipment that entails a large capital expense, such as stainless-steel vessels, with low-cost and adaptable single-use flow paths. More and more single-use processing components are becoming available, thus increasing the amount of production-scale manufacturing that relies on single-use technology.

PharmTech:
What is the most common demand your clients are currently making of you?

MacDonald:
The most common demands from our customers are traceability of raw materials and materials that are free of animal byproducts.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
20%
Do not use QbD
25%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here